Epigenetic regulations in the IFNγ signalling pathway: IFNγ-mediated MHC class I upregulation on tumour cells is associated with DNA demethylation of antigen-presenting machinery genes

Oncotarget

Volumn 5, Issue 16, 2014, Pages 6923-6935

  Vlková, Veronika ^a   Sˇtěpánek, Ivan ^a   Hrušková, Veronika ^a   Sˇenigl, Filip ^a   Mayerová, Veronika ^a   Sˇrámek, Martin ^a   Sˇímová, Jana ^a   Bieblová, Jana ^a   Indrová, Marie ^a   Hejhal, Tomáš ^a   Dérian, Nicolas ^b,c   Klatzmann, David ^b,c   Six, Adrien ^b,c   Reiniš, Milan ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^b Sorbonne Université   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

5 azacytidine; DNA demethylation; IFN signalling; MHC class I downregulation; Tumour immunology

Indexed keywords

AZACITIDINE; DNA; DNA METHYLTRANSFERASE INHIBITOR; GAMMA INTERFERON; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; JANUS KINASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; STAT PROTEIN; TRANSCRIPTOME; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 2; UNCLASSIFIED DRUG;

ACETYLATION; ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; EPIGENETICS; GENE LOCUS; GENE SEQUENCE; GENETIC REGULATION; HISTONE ACETYLATION; METHYLATION; MOUSE; NONHUMAN; PROMOTER REGION; TUMOR CELL; TUMOR CELL LINE; UPREGULATION; ANIMAL; ANTIGEN PRESENTATION; C57BL MOUSE; DNA METHYLATION; DOWN REGULATION; FIBROSARCOMA; GENE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

ANIMALS; ANTIGEN PRESENTATION; DNA METHYLATION; DOWN-REGULATION; EPIGENESIS, GENETIC; FIBROSARCOMA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MHC CLASS I; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84907087914     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2222     Document Type: Article

References (37)

1. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007; 128: 683-692.
2. Esteller M. Epigenetics in cancer. N Engl J Med. 2008; 358: 1148-1159.
3. Sigalotti L, Coral S, Fratta E, Lamaj E, Danielli R, Di Giacomo AM, Altomonte M, Maio M. Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy. Semin Oncol. 2005; 32: 473-478.
4. Tomasi TB, Magner WJ, Khan AN. Epigenetic regulation of immune escape genes in cancer. Cancer Immunol Immunother. 2006; 55: 1159-1184.
5. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today. 1997; 18: 89-95.
6. Bubeni´k J. Tumour MHC class I downregulation and immunotherapy (Review). Oncol Rep. 2003; 10: 2005-2008.
7. Reinisˇ M. Immunotherapy of MHC class I-deficient tumors. Future Oncol. 2010; 6: 1577-1589.
8. Seliger B. Novel insights into the molecular mechanisms of HLA class I abnormalities. Cancer Immunol Immunother. 2012; 61: 249-254.
9. Garrido F, Cabrera T, Aptsiauri N. "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy (Review). Int J Cancer. 2010; 127: 249-256.
10. Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C. Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin. Tissue Antigens. 2000; 56: 327-336.
11. Garcia-Lora A, Martinez M, Algarra I, Gaforio JJ, Garrido F. MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int J Cancer. 2003; 106: 521-527.
12. Gabathuler R, Reid G, Kolaitis G, Driscoll J, Jefferies WA. Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing. J Exp Med. 1994; 180: 1415-1425.
13. Setiadi AF, David MD, Seipp RP, Hartikainen JA, Gopaul R, Jefferies WA. Epigenetic control of the immune escape mechanisms in malignant carcinomas. Mol Cell Biol. 2007; 27: 7886-7894.
14. Christova R, Jones T, Wu PJ, Bolzer A, Costa-Pereira AP, Watling D, Kerr IM, Sheer D. P-STAT1 mediates higher-order chromatin remodelling of the human MHC in response to IFNgamma. J Cell Sci. 2007; 120: 3262-3270.
15. Manning J, Indrova M, Lubyova B, Pribylova H, Bieblova J, Hejnar J, Simova J, Jandlova T, Bubenik J, Reinis M. Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours. Immunology. 2008; 123: 218-227.
16. Setiadi AF, Omilusik K, David MD, Seipp RP, Hartikainen J, Gopaul R, Choi KB, Jefferies WA. Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res. 2008; 68: 9601-9607.
17. Khan AN, Gregorie CJ, Tomasi TB. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother. 2008; 57: 647-654.
18. Simova J, Pollakova V, Indrova M, Mikyskova R, Bieblova J, Stepanek I, Bubenik J, Reinis M. Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status. British Journal of Cancer. 2011; 105: 1533-1541.
19. Smahel M, Si´ma P, Ludvi´kova´ V, Marinov I, Pokorna´ D, Vonka V. Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. Vaccine. 2003; 21: 1125-1136.
20. Martini M, Testi MG, Pasetto M, Picchio MC, Innamorati G, Mazzocco M, Ugel S, Cingarlini S, Bronte V, Zanovello P, Krampera M, Mosna F, Cestari T, Riviera AP, Brutti N, Barbieri O, Matera L, Tridente G, Colombatti M, Sartoris S. IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine. 2010; 28: 3548-3557.
21. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994; 264: 1415-1421.
22. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immuno. 2006; 6: 836-848.
23. Serrano A, Castro-Vega I, Redondo M. Role of gene methylation in antitumor immune response: implication for tumor progression. Cancers (Basel). 2011; 3: 1672-1690.
24. Xue ZT, Sjo¨gren HO, Salford LG, Widegren B. An epigenetic mechanism for high, synergistic expression of indoleamine 2,3-dioxygenase 1 (IDO1) by combined treatment with zebularine and IFN-γ: Potential therapeutic use in autoimmune diseases. Molecular Immunology. 2012; 51: 101-111.
25. Niehrs C. Active DNA demethylation and DNA repair. Differentiation. 2009; 77: 1-11.
26. Vaissie`re T, Sawan C, Herceg Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res. 2008; 659: 40-48.
27. Creusot F, Acs G, Christman JK. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine. J Biol Chem. 1982; 257: 2041-2048.
28. Thillainadesan G, Chitilian JM, Isovic M, Ablack JN, Mymryk JS, Tini M, Torchia J. TGF-β-dependent active demethylation and expression of the p15ink4b tumor suppressor are impaired by the ZNF217/CoREST complex. Mol Cell. 2012; 46: 636-649.
29. Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, Wang Q, Chia D, Goodglick L, Kurdistani SK. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol. 2009; 174: 1619-1628.
30. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996; 56: 21-26.
31. Smahel M, Sobotkova E, Bubenik J, Simova J, Zak R, Ludvikova V, Hajkova R, Kovarik J, Jelinek F, Povysil C, Marinov J, Vonka V. Metastatic MHC class I-negative mouse cells derived by transformation with human papillomavirus type 16. Br J Cancer. 2001; 84: 374-380.
32. Bubeni´k J, Indrova´ M, Nemeckova´ S, Malkovsky` M, Von Broen B, Pa´lek V, Anderli´kova´ J. Solubilized tumour-associated antigens of methyl-cholanthrene-induced mouse sarcomas. Comparative studies by in vitro sensitization of lymph-node cells, macrophage electrophoretic mobility assay and transplantation tests. Int J Cancer. 1978; 21: 348-355.
33. Bubeni´k J, Koldovsky` P, Svoboda J, Klement V, Dvora´k R. Induction of tumours in mice with three variants of rous sarcoma virus and studies on the immunobiology of these tumours. Folia Biol (Praha). 1967; 13: 29-39.
34. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 1997; 57: 3325-3330.
35. Torella D, Curcio A, Gasparri C, Galuppo V, De Serio D, Surace FC, Cavaliere AL, Leone A, Coppola C, Ellison GM, Indolfi C. Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibiton of STAT-1 activation. Am J Physiol Heart Circ Physiol. 2007; 292: H2935-2943.
36. Lukas J, Mazna P, Valenta T, Doubravska L, Pospichalova V, Vojtechova M, Fafilek B, Ivanek R, Plachy J, Novak J, Korinek V. Dazap2 modulates transcription driven by the Wnt effector TCF-4. Nucleic Acids Res. 2009; 37: 3007-3020.
37. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, Herman JG, Baylin SB. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet. 2002: 31: 141-149.